REM-422

A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS

More Information

Trial Status
Accepting patients
Trial Phase
Phase 1
Enrollment
100 patients (estimated)
Sponsors
Remix Therapeutics
Tags
MYB mRNA Degrader
Trial Type
Treatment
Last Update
3 months ago
SparkCures ID
1848
NCT Identifier
NCT06297941

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.